🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

100,80 USD

Máx. histórico

123,62

845 días

Caída desde máximo

-18,46%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,49%

Cierre anterior

100,31

Rango de hoy

100,26 – 100,83

Volumen hoy

748.573

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,44%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,41 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 12 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/10/2024 116,82 116,82 110,76 112,08 -3,95% 5,19% 677.000
18/10/2024 116,25 117,47 115,01 116,69 +0,90% 2,12% 516.800
17/10/2024 112,67 116,16 112,40 115,65 +2,80% 3,34% 648.000
16/10/2024 112,83 113,69 111,78 112,50 +0,48% 1,70% 644.200
15/10/2024 110,77 112,55 110,04 111,96 +1,12% 2,27% 527.500
14/10/2024 113,10 113,86 110,24 110,72 -1,31% 3,20% 416.700
11/10/2024 108,60 112,25 108,25 112,19 +3,72% 3,68% 486.100
10/10/2024 108,28 108,49 105,05 108,17 -1,01% 3,18% 542.500
09/10/2024 107,64 109,81 106,81 109,27 +1,08% 2,79% 309.900
08/10/2024 107,28 109,26 106,67 108,10 +1,41% 2,42% 506.400
07/10/2024 107,24 108,37 106,30 106,60 -1,10% 1,93% 342.200
04/10/2024 107,96 108,63 105,98 107,79 +1,15% 2,45% 296.400
03/10/2024 105,37 106,81 103,65 106,56 +1,31% 3,00% 453.300
02/10/2024 105,42 106,65 103,93 105,18 -0,62% 2,58% 449.900
01/10/2024 109,88 111,74 105,69 105,84 -3,56% 5,51% 503.300
30/09/2024 107,27 110,33 107,27 109,75 +2,23% 2,85% 609.600
27/09/2024 106,03 108,52 104,94 107,36 +2,81% 3,38% 673.100
26/09/2024 109,29 109,37 101,88 104,43 -3,26% 6,85% 1.033.300
25/09/2024 112,14 112,14 107,50 107,95 -3,41% 4,14% 673.300
24/09/2024 111,12 113,21 110,69 111,76 +0,36% 2,27% 600.500
23/09/2024 111,71 113,44 109,67 111,36 +1,19% 3,37% 583.100
20/09/2024 108,74 110,47 107,61 110,05 +1,37% 2,63% 1.162.300
19/09/2024 110,66 111,36 107,18 108,56 +0,39% 3,78% 943.600
18/09/2024 104,99 109,94 104,50 108,14 +2,46% 5,18% 611.600
17/09/2024 107,87 109,05 104,54 105,54 -1,83% 4,18% 543.400
16/09/2024 105,60 107,74 104,79 107,51 +1,86% 2,79% 449.100
13/09/2024 104,10 107,00 104,03 105,55 +1,46% 2,85% 1.119.800
12/09/2024 102,30 105,30 101,60 104,03 +2,04% 3,62% 808.100
11/09/2024 98,87 102,09 98,18 101,95 +2,90% 3,95% 645.600
10/09/2024 100,92 100,93 98,57 99,08 -1,51% 2,34% 548.000